3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Lymphoid
3
Other hematologic neoplasm
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Other
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Weight Loss
1
Urinary Bladder Neoplasms
1
Motor Activity
1
Malnutrition
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
161
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
96
Docetaxel
92
Radiosurgery
91
Prednisone
81
Androgen Antagonists
81
Abiraterone Acetate
79
Radiotherapy
75
apalutamide
66
Cisplatin
65
darolutamide
62
Ipilimumab
61
Biopsy
61
abiraterone
57
cabozantinib
55
Carboplatin
55
Leuprolide
52
enfortumab vedotin
50
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diet
×
Genitourinary
×
1 year
×
Clear all
NCT06002269
2025-07-20
BOOST
University of Utah
Phase NA
Completed
8 enrolled